HC Wainwright

Bitcoin Miner CleanSpark Has 'Solid, Albeit Relatively Quiet' Quarter, Ready For Growth, Says Analyst
Plug Power Misses Q2 Revenues, Analysts Focus On Electrolyzer Deployments: 'The Bar Was Set Low'
These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'
Plug Power Misses Q2 Revenues, Analysts Focus On Electrolyzer Deployments: 'The Bar Was Set Low'
These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'
Coinbase Global Is 'Doing Almost Everything Right': 7 Analysts React To Q1 Results
Coinbase Q1 Earnings Preview: What Analysts Are Saying, SEC Regulation & Other Items To Watch

HC Wainwright Recent News

These 2 Analysts Are Bullish Despite EV Equipment Maker Blink Charging's Wider Loss
Electric vehicle (EV) equipment provider Blink Charging Co. (NASDAQ: BLNK) reported revenues of $11.5 million, ahead of the consensus estimate of $9.8 million. However, its adjusted loss came in at 41 cents per share, versus Street expectations of a loss of 37 cents a share.
Why InflaRx Shares Are Ripping Higher Thursday
InflaRx N.V. (NASDAQ: IFRX) shares are rallying hard Thursday. Here's why. 
Why Plug Power Analysts Are Bullish After Hydrogen Green Energy Company's Investor Day
Plug Power Inc. (NASDAQ: PLUG) announced an acquisition, partnerships, products and updated guidance at its 2021 Plug Symposium.
Psyched: Field Trip Gets $20 Price Target, DEA Seeks To Increase Psilocybin Production Limits, Synthesis Closes $7.25M Series A
Contents
Field Trip Stock Could Climb 300% In One Year
On Wednesday, HC WainWright began coverage of Field Trip Health (NASDAQ: FTRP), a company in the psychedelics space, which is developi
What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict
FibroGen, Inc. (NASDAQ: FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the company's new drug application for roxadustat. The committee is scheduled to meet between 9:30 a.m. and 5:30 p.m.
Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated
Regeneron Pharmaceuticals Inc.'s (NASDAQ: REGN) robust pipeline and attractive valuation has prompted an analyst at HC Wainwright to join the bullish camp.
Wall Street Analysts See These 4 Stocks As Winners Moving Into December
The advancements with COVID-19 vaccines of Pfizer Inc. (NYSE: PFE), Moderna Inc. (NASDAQ: MRNA), and AstraZeneca Inc. (NASDAQ:
Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment
Biotech Stock On The Radar: Nabriva And Its Novel Antibiotic Portfolio
HC Wainwright Hikes Karyopharm Price Target On Accelerated Drug Approval
G1 Therapeutics Investors Recoil, Analysts Bullish In Wake Of Trilaciclib Results
Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?
Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade
Sell-Side Analysts See Upside Potential In Zynerba
HC Wainwright: Celyad's CAR-T Pipeline Has Potential
HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets
Cesca Therapeutics Snags Bullish HC Wainwright Initiation On CAR-T Opportunity
Jounce Therapeutics Stock Slides On Disappointing Data, Wells Fargo Downgrades
HC Wainwright Says Aerpio Pharma Flies Under The Radar Due To OTC Listing, Projects 150% Upside
Analysts See 100% Upside To Rigel After Tavalisse Approval
HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold
For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst'

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved